Aim We hypothesised that some of the genetic risk for gestational diabetes (GDM) is due to the fetal genome affecting maternal glucose concentrations. Previously we found associations between fetal IGF2 gene variants and maternal glucose concentrations in late pregnancy.
Introduction
Familial studies suggest that the risk for a pregnant woman developing gestational diabetes (GDM) might be partially genetically mediated. However knowledge of GDM genetics has lagged behind that of non-gravid diabetes [1, 2] . Only one genome-wide association study (GWAS) focussing on GDM has been published to date [3] , with another one focussing on its endophenotype, maternal glucose concentrations in pregnancy [4] . Other studies have picked candidate genes from type 2 diabetes (T2DM) GWASs to test their associations with GDM, using the assumption that the genetic architecture of GDM is very similar to that of T2DM [5, 6] . Meta-analyses have confirmed some of the associations between genetic variants and GDM [7, 8] , and like with T2DM, pathway analysis of these variants show an enrichment of insulin secretion genes [1] .
Despite the known GDM-related variants relatively little of its heritability has been explained [9] . Whilst further risk single nucleotide polymorphisms (SNPs) may emerge through the GWASs of larger populations with greater statistical power, other heritability may be explained by epistasis or copy number variants. Also, following the suggestion that the fetal genome may influence maternal pregnancy metabolism [10] , we hypothesised that imprinted fetal growth genes might alter maternal glucose concentrations and GDM risk [11] . These genes are related to parent of origin effects reflecting the separate reproductive needs of each parent [12] . Paternally-expressed imprinted genes tend to enhance fetal growth, whereas maternally-expressed genes tend to reduce it, probably through changes in fetal demand and supply [13] .
We first tested our hypothesis in a mouse model where H19 genes and Igf2 control elements (regulators of Igf2 expression) were disrupted [14] . On day 16 of the 21.5 days of pregnancy
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essentially wild type mice carrying litters where half of the fetuses were H19 knockouts had higher blood glucose concentrations than those of genetically-matched controls. These studies were followed by genotyping in humans where 4 paternally-expressed fetal IGF2 SNPs were associated with late pregnancy maternal glucose concentrations [15] . The effect of imprinting was confirmed through lack of associations with the equivalent maternallytransmitted alleles. More recently we have found associations between various fetal imprinted gene SNP alleles and maternal blood pressure and risk of gestational hypertension [16] .
Although the mechanism of how the fetal genotype can affect maternal glucose concentrations in pregnancy is unknown, we hypothesised that it involves the fetal-derived placenta through the secretion of hormones and regulatory proteins [11] . Hence in the present study, to explore the hypothesis further, we genotyped SNPs in a number of fetal imprinted genes that are expressed in the placenta at some stage of fetal development [17] . We tested their associations with late pregnancy maternal glucose concentrations in our Cambridge Baby Growth and Wellbeing cohorts, initially focussing on just paternally-expressed fetal genes because they are independent of confounding by the maternal genotype. We constructed a composite fetal imprinted gene allele score to estimate the extent to which polymorphic variations in these genes are associated with variance in late pregnancy maternal glucose concentrations and GDM in our cohorts. We then we used data from Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study participants [18] to perform replication testing and meta-analyses of the associations.
Material and Methods

Cohort 1: Cambridge Baby Growth Study
The prospective, longitudinal Cambridge Baby Growth Study recruited mothers (and their partners and offspring) attending early pregnancy ultrasound clinics at the Rosie Maternity
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Hospital, Cambridge, U.K. between the years 2001-2009 [19] . At around 28 weeks of gestation the mothers underwent a 75g oral glucose tolerance test (OGTT) after fasting overnight. Venous blood was collected just prior to and 60 min. after the consumption of the glucose load for the measurement of plasma glucose and insulin concentrations. In total, 845 DNA trios were collected from the families of 1,074 mothers recruited to the study for whom OGTT data were available. Blood and/or mouth swab samples for DNA extraction were collected from the father and the offspring after birth. In this cohort 96.9% of the offspring were White, 0.8% were mixed race, 0.6% were Black (African or Caribbean), 0.8% were Oriental and 0.9% were Indo-Asian. Using International Association of Diabetes in Pregnancy Study Groups (IADPSG) thresholds [20] the GDM prevalence was 10.2%.
Cohort 2: Cambridge Wellbeing Study
The Cambridge Wellbeing Study is a retrospective study of mothers, fathers and children where the mother had delivered a full term, singleton baby at the Rosie Maternity Hospital, Cambridge, U.K. between the years 1999-2000 [15] . Routinely collected clinical data were available on offspring birth weight and mother's whole blood glucose levels measured 60 min. after the oral consumption of 50g glucose at 27-29 weeks of gestation. Exclusion criteria were pre-existing maternal hypertension and diabetes treatment during early pregnancy. All the offspring were White. We sought permission from the mother's General Practitioner to approach the family to collect their DNA sample by mouth swab kits. In total 315 DNA trios were collected out of 563 women who consented. Using IADPSG thresholds [20] the GDM prevalence was 8.2%. Petry et al., HAPO is a large multi-national prospective study of pregnancy that has been described previously, including its exclusion criteria [18, 21] . Pregnant study participants, recruited early in gestation between the years 2000-2006, underwent a 75g OGTT as close to 28 weeks of gestation as possible. Glucose concentrations were measured centrally. Those women with plasma glucose concentrations > 5.8mmol/L (fasting) or 11.1mmol/L (two hours into the OGTT), 1.7% of the total population, were excluded from the study due to having overt diabetes. DNA samples from 1,424 mother and baby study participants of European ancestry were used for a GWAS of maternal glycaemic and newborn anthropometric traits [4] . Using IADPSG thresholds [20] the GDM prevalence was 14.8%.
Cohort 3: Hyperglycemia and Adverse Pregnancy Outcome Study
Ethical Approval
The Cambridge Baby Growth and Wellbeing Studies were approved by the local ethics committee, Addenbrooke's Hospital, Cambridge, U.K. In the HAPO Study the protocol was approved by each field centre's local institutional review board. Written informed consent was obtained from the parents in each of the cohorts studied, including consent for inclusion of their infants in the study.
Biochemical Measurements
Blood glucose concentrations were measured using a routine glucose oxidase-based method.
Maternal plasma insulin concentrations were measured using a DSL ELISA kit (London, U.K.) according to the manufacturer's instructions.
Gene Selection and Genetics
For the Cambridge Baby Growth and Wellbeing Studies genomic DNA was extracted from blood samples or mouth swabs using an Autopure LS Machine (Qiagen Ltd., Crawley, U.K.). Table 3 ). The one exception to this was 11 tagging IGF2 SNPs which were identified by Rodríguez et al. [23] . The DNA samples were genotyped using Kompetitive Allele Specific PCR assays, which are competitive allele-specific PCR SNP genotyping assays using fluorescence resonance energy transfer quencher cassette oligonucleotides (designed and performed by LGC Genomics, Hoddesdon, U.K.). The genotypes that were used in this study were consistent with Hardy Weinberg equilibrium (p>0.05 using the χ 2 test) and had a repeat genotyping discordancy rate of <1.0%.
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HAPO DNA samples were genotyped using the Illumina Human 610 Quad v1 B SNP array (Illumina Inc., San Diego, U.S.A.) and additional SNPs were imputed using BEAGLE [24] .
For the present study the SNP genotypes that were tested from the HAPO population were those that were used in the composite fetal allele imprinted gene allele score (namely paternally-transmitted fetal IGF2 rs10770125 and INS rs2585, and maternally-transmitted fetal KCNQ1OT1 rs231841 and KCNQ1OT1 rs7929804).
Placental KCNQ1(OT1) Gene Expression
KCNQ1 and KCNQ1OT1 expression were measured in term placentas by RT-qPCR with YWHAZ, TOP1 and UBC used as reference genes [25] (see the Supplementary Material for
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detailed methodology). Expression was then related to the fetal KCNQ1OT1 SNP alleles that were associated with maternal glucose concentrations.
Statistical Analyses and Composite Score Formulation
With different glucose loads used in the two Cambridge cohorts, post-load maternal glucose responses were standardised by calculating z-scores separately in each cohort (using the mean and standard deviation for glucose concentrations from all the women in each cohort), and then analysed as a single group (with more statistical power) of 1,160 family DNA trios with maternal glucose z-scores [15] . Each parentally-transmitted fetal SNP allele was tested for association with the 60 min. postload maternal glucose concentration z-score in an unadjusted linear regression model (i.e.
paternally-and maternally-transmitted SNP alleles were tested separately). Where needed robust regression was used where the standard errors were estimated using the Huber-White score, where the fetal SNP allele was known a score of 1 was added if it was the one that was associated with higher glucose concentrations and 0 if it was the one associated with lower concentrations. In cases where the allele was missing (due to genotyping error or uninformative trio genotypes) the combined frequency amongst both cohorts of the glucose increasing allele was added to the score. After each new allele was added to the gene score associations with the 60 min. post-load maternal glucose concentration z-score was retested in a linear regression model. This process was continued, adding scores from one SNP allele at a time, whilst the adjusted r 2 of the linear regression model was increasing. Once the r 2 of the model reduced (due to greater noise brought about by the addition of an allelic score from a SNP that was more weakly associated with the maternal glucose concentrations) this process was halted and the previous allele score was adopted as the final score (an unweighted estimated allele count). To remove potential overfitting due to linkage disequilibrium further allele scores were calculated removing effects due to each of the individual IGF2 SNP alleles in the full allele score. Associations with GDM were tested using logistic regression, both unadjusted and adjusted for pre-pregnancy maternal body mass index (BMI) and age.
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The meta-analysis was performed using correlation coefficients of the associations between the fetal alleles and week 28 maternal glucose concentrations 60 min. after a glucose load.
For the Cambridge cohorts correlation coefficients were available to us. For the HAPO Study participants standardised β-coefficients were available to us and correlation coefficients were estimated from these using the method of Peterson and Brown [27] . The meta-analysis used the DerSimonian-Laird approach [28] for random effects models to allow for any potential heterogeneity, implemented into the R package Metacor version 1.0-2 [29] . Meta-analysis heterogeneity was assessed using Medcalc version 17.2 (Ostend, Belgium).
Correction for multiple testing was considered unnecessary as only one primary association was tested (i.e. the allelic score with the maternal glucose z-scores). All other associations
were considered secondary and a p-value of <0.05 was considered statistically significant. 
Results
Associations with Maternal Glucose Concentration Z-Scores and Gestational Diabetes in the Cambridge Baby Growth and Wellbeing Studies
The ten strongest unadjusted associations between fetal imprinted gene alleles and maternal 60 min. glucose concentration z-scores are shown in Table 1 , including 4 IGF2 SNPs previously reported [15] . All other SNP alleles were associated at p>0.01. The composite fetal imprinted gene allele score comprised the scores from the genotypes of the first four The composite fetal imprinted gene allele score was also associated with the unadjusted fasting blood glucose concentrations (p=0.03; n=671 in the Cambridge Baby Growth Study).
The score explained 0.6% of the maternal fasting glucose concentration variance and for each increase of the gene score by one there was an associated increase in maternal glucose 
Replication in HAPO and Meta-analysis
None of the four fetal SNPs used in the composite allele score or the composite allele score itself were significantly associated with unadjusted maternal glucose concentrations 60 min.
into the OGTT in the HAPO Study participants (Table 3 ). However two of the univariate associations and the composite fetal imprinted gene allele score association were unidirectional with those from the Cambridge cohorts, so that in the meta-analysis the inclusion of the HAPO Study data strengthened the associations with maternal 60 min.
glucose concentrations found in the Cambridge cohorts for the paternally-transmitted fetal SNP alleles from the INS/IGF2 region, rs2585 and rs10770125 (p=3.6x10 -5 and p=3.2x10 -8 , respectively) (Fig. 2) . In contrast the meta-analysis showed no significant associations with the maternally-transmitted fetal SNP alleles from the KCNQ1OT1 region, rs231841 and rs7929804 (p=0.4 and p=0.2, respectively). The composite fetal imprinted gene allele score association with maternal 60 min. glucose concentrations found in the Cambridge cohorts was strengthened in the meta-analysis (p=1.3x10 -8 ) (Fig. 3) . None of the meta-analyses had significant heterogeneity (Supplementary Table 5 ).
Placental KCNQ1(OT1) Gene Expression
Maternally-transmitted fetal rs231841 allele was associated with placental KCNQ1 expression at birth adjusted for the expression of the panel of reference genes (n=21 samples; p=0.04) in the Cambridge Baby Growth Study but not with placental KCNQ1OT1
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expression (n=20; p=0.2) (Supplementary Table 6 ). Maternally-transmitted fetal rs7929804
was not associated with the expression of either gene (n=20 for both; p=0.9 and 0.3, respectively).
Discussion
In this study we developed a composite fetal imprinted gene allele score that was strongly associated with late pregnancy maternal glucose concentrations and GDM in the two independent Cambridge cohorts. Significance of the association was not reached in HAPO Study participants with European ancestry, although the association was unidirectional with the associations in the Cambridge cohorts and genome wide significance was reached by meta-analysis. The lack of significant replication of associations outside of the meta-analysis for the individual SNP alleles and the composite score is perhaps not surprising given that the HAPO Study excluded those with the highest glucose concentrations and participants with European ancestry were recruited from 4 different sites in the U.S.A., 2 in the U.K., 2 in
Australia and 1 in Canada [4] whereas both Cambridge cohorts were recruited via the same maternity hospital in the U.K. and so may be more homogeneous. The association between maternal glucose concentrations and the composite fetal imprinted gene allele score in the meta-analysis suggests that the fetal genes that were tested, with the INS/IGF2 region in particular, may make a small but significant contribution to the maternal glucose concentrations in pregnancy. This expands our previous finding of 4 paternally-transmitted fetal IGF2 SNP alleles that were also associated with maternal glucose concentrations in the two Cambridge cohorts [15] . In our meta-analysis the association of one of these IGF2 SNP alleles (rs10770125) with maternal glucose concentrations reached genome wide significance, the first fetal SNP allele to do so.
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Although variants were tested from 15 different paternally-expressed imprinted genes, the ten variants most strongly associated in our data were found in only two fetal 
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the primary association is with KCNQ1 rather than KCNQ1OT1 per se, at least for rs231841.
Interestingly a number of studies have previously found associations between genetic variation in KCNQ1 and GDM [7, [33] [34] [35] [36] [37] . Of the two SNPs used in the composite score rs231841 shows a degree of linkage disequilibrium (r 2 =0.75, D'=0.88) in the Thousand Genome Project [26] with rs231353 which itself is associated with T2DM [38] . The other SNP rs7929804 is in linkage disequilibrium with rs10766218 (r 2 =0.8, D'=1) [26] which is an eQTL for KCNQ1, whose expression is associated with insulin secretion in vitro [39] . This is consistent with the association that we found with the insulin increment after the glucose load. The associations with these fetal alleles therefore appear plausible.
The fact that in the meta-analysis of the univariate fetal SNP allele associations the KCNQ1(OT1) associations were not significant raises the possibility that their associations in the Cambridge cohorts are confounded by the maternal ones. Indeed unlike associations with paternally-transmitted fetal alleles, associations with maternally-transmitted fetal alleles are extremely difficult to distinguish from maternal genotype effects. Maternal allelic transmission to the fetus obviously originates from the maternal genotype and is therefore not biologically independent of it. Indeed for rs231841 there is evidence in the Cambridge cohorts for a direct maternal genotype association with their glucose concentrations, its pvalue being lower than that with the maternally-transmitted fetal allele. However there is possibly an additional fetal genetic effect because the association with the maternallytransmitted fetal allele always has a lower p-value than that with the untransmitted maternal allele and the association of the fetal genotype with placental KCNQ1 expression is stronger than that with the maternal genotype. We must be cautious about these interpretations, however, given the lack of replication of these univariate associations in HAPO; it remains
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possible that all the fetal associations with maternal GDM-related phenotype are mediated through IGF2 once confounders have been fully accounted for.
Although the associations between the maternal glucose concentrations and the composite fetal imprinted gene allele score appear robust given the meta-analysis, with their lack of heterogeneity, the study does have limitations in addition to those outlined previously [15] .
Firstly the analysis used to construct the composite fetal imprinted gene allele score is post hoc in nature. However we set out to construct it this way due to the lack of established fetal imprinted genes that we tested, the contribution of the fetal genome to variation in maternal glucose concentrations appears to be small although highly statistically significant. In combination with maternal risk genotypes these fetal alleles may increase the risk of maternal GDM.
Legends to Figures   Fig. 1 Associations between maternal glucose concentration z-scores one hour after the oral consumption of a glucose load and alleles from the 4 SNPs that are used in the composite fetal imprinted gene allele score: (a) the paternally-transmitted fetal allele, (b) the maternallytransmitted fetal allele and (c) the maternal allele that was not transmitted to the fetus. Data are mean (95 % confidence interval). Odds ratios are mean (95 % confidence interval). Table 3 Associations between the four fetal SNP alleles used in the composite fetal imprinted gene allele score, and the score itself, and maternal glucose concentrations one hour after the oral consumption of a 75g glucose load in HAPO Study participants with European ancestry.
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N/A = not applicable.
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